Citation for published version


DOI

https://doi.org/10.1016/j.eururo.2015.10.039

Link to record in KAR

http://kar.kent.ac.uk/54745/

Document Version

Author's Accepted Manuscript

Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research
The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record.

Enquiries
For any further enquiries regarding the licence status of this document, please contact:
researchsupport@kent.ac.uk

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html
The Role of Protein Modelling in Predicting the Disease Severity of Cystinuria

Kathie A Wong\textsuperscript{a,1,*}, Mark Wass\textsuperscript{b,1}, Kay Thomas\textsuperscript{a}

© 2016 This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

A Urology Centre, Guy’s and St. Thomas’ NHS Foundation Trust, London, SE1 9RT, UK

B School of Biosciences, University of Kent, Canterbury Kent, UK

*Corresponding author. Urology Centre, Guy’s and St. Thomas’ NHS Foundation Trust, London SE1 9RT, UK. Tel. +44 79 12225938; Fax: +44 20 71997188.

E-mail address: kathie.wong@gmail.com (K.A. Wong).

1 These authors are joint first authors.
Mutations in one of two genes SLC3A1 and SLC7A9 are responsible for the majority of cystinuria phenotypes. A defective renal tubular protein transporter causes high urinary levels of cystine and the dibasic amino acids, lysine, arginine and ornithine. Cystine is relatively insoluble in urine and forms stones. We have found 57 different mutations in our UK cohort[1]. Most are missense mutations and it is unclear what effect they have on protein function and how this translates to phenotype.

The aim of this study was to use protein modelling to investigate how missense mutations may affect protein function. Limited experimental data is available as experimental techniques are time-consuming and results would lag significantly behind the rate at which new mutations are being reported. Understanding how individual mutations can cause protein dysfunction could allow us to predict a patient’s disease severity and tailor individual management more effectively. We modelled the b(0+)AT protein encoded by SLC7A9 using the Phyre2 web server, and other validated software [2-5].

The missense mutations were scored by an investigator blind to the clinical data into those predicted to cause a low/low-medium effect=1 or high/high-medium effect=2. This was based on several factors including the proximity of the mutation to the predicted functional sites and size of conformational change. Large genomic rearrangements were assumed to cause significant protein dysfunction therefore all other (non-missense) mutations were
assigned a score of 2. An overall severity score was calculated for 26 patients based on the sum of the score of each individual mutation. For example, a patient with a predicted low-effect missense mutation and a frameshift mutation would score 3 (1+2).

When comparing patients with a score of 4 versus a score of 3, there was no difference between the levels of cystine (201 μmol/mmolCr IQR 161 to 231 vs 154 μmol/mmolCr IQR 133.7 to 191.3, p=0.2545) or lysine (629.5 μmol/mmolCr IQR 593.2 to 814.6 vs 569.5 μmol/mmolCr IQR 403.6 to 807.5, p=0.2887). Patients who scored 4 had higher levels of arginine (383 μmol/mmolCr IQR 283 to 392.7 vs 70 μmol/mmolCr IQR 36.38 to 237.3, p=0.0151) and ornithine (120.2 μmol/mmolCr IQR 97.67 to 153.1 vs 94 μmol/mmolCr IQR 68.38 to 111, p=0.0482) than patients who scored 3. They also experienced a higher number of stone episodes (0.5/yr IQR 0.0 to 1.0 vs 0.0/yr IQR 0 to 0.3, p=0.0451). Only three patients scored less than 3, precluding statistical analysis.

Our results suggest our model may help determine a patient’s phenotype. The lack of statistical difference for cystine and lysine may be explained by limitations in cystine measurements and other transporter mechanisms involved in lysine transport.

Clearly, a patient’s genotype can only determine part of a patient’s disease profile, which may also be influenced by modifier genes and complex genetic and environmental interactions. More collaborative work is needed to explore
our hypothesis. This approach has given us insight into how the different missense mutations may cause the range of phenotypes seen in Cystinuria and is a step closer to a personalised approach to the management of these patients.

References

Figure 1 Structural analysis of mutations present in b(0+)AT. A) A structural model of b(0+)AT was generated and residues involved in amino acid transport identified (cyan) and mutations mapped on (red) to analyse their potential structural and functional effect. B) p.Gly105Arg is located at the end of the channel where amino acids are transported. C) Some mutations (p.Arg171Trp, p.Arg333Trp) are located close to the end of the membrane and could affect stability in the membrane.